Neoadjuvant paradigm for accelerated drug development: An ideal model in bladder cancer

Oncologist

Volumn 18, Issue 8, 2013, Pages 933-940

  Chism, David D ^a   Woods, Michael E ^a   Milowsky, Matthew I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Neoadjuvant; Urothelial cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TRASTUZUMAB; VEMURAFENIB; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CYSTECTOMY; GENOMIC INSTABILITY; HEARING IMPAIRMENT; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MELANOMA; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

BLADDER CANCER; NEOADJUVANT; UROTHELIAL CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG DISCOVERY; GENOMIC INSTABILITY; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84883220572     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0023     Document Type: Article

References (62)

1. Seymour L, Ivy SP, Sargent D et al. The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 2010;16:1764-1769.
2. McKee AE, Farrell AT, Pazdur R et al. The role of the U.S. Food and Drug Administration review process: Clinical trial endpoints in oncology. The Oncologist 2010;15(suppl 1):13-18.
3. Johnson JR, Ning YM, Farrell A et al. Accelerated approval of oncology products: The Food and Drug Administration experience. J Natl Cancer Inst 2011; 103:636-644.
4. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 2005;365: 60-62.
5. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. Lancet Oncol 2012;13: 1152-1160.
6. Song WA, Zhou NK, Wang W et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: An updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010;5:510-516.
7. Robova H, Rob L, Halaska MJ et al. High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer. Gynecol Oncol 2013;128:49-53.
8. Tajima H, Ohta T, Kitagawa H et al. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med 2012;3:787-792.
9. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
10. Rock EP, Kennedy DL, Furness MH et al. Patient-reported outcomes supporting anticancer product approvals. J Clin Oncol 2007;25:5094-5099.
11. Barker AD, Sigman CC, Kelloff GJ et al. I-SPY 2: An adaptive breast cancer trial design in the setting ofneoadjuvantchemotherapy. Clin Pharmacol Ther 2009;86:97-100.
12. Lips EH, Mukhtar RA, Yau C et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat 2012;136:35-43.
13. Esserman LJ, Berry DA, DeMichele A et al. Pathologic complete response predicts recurrencefree survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB 150007/ 150012, ACRIN 6657 J Clin Oncol 2012;30:3242-3249.
14. Guarneri V, Frassoldati A, Bottini A et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989-1995.
15. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvantpertuzumabandtrastuzumab in women with locally advanced, inflammatory, or early HER2-positive breastcancer(Neo Sphere):Arandomisedmulticentre, open-label, phase2trial. Lancet Oncol 2012;13:25-32.
16. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366:2438-2441.
17. Sonpavde G, Goldman BH, Speights VO et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009;115:4104-4109.
18. Siegel R, Naishadham D, Jemal A. Cancerstatistics, 2012. CA Cancer J Clin 2012;62:10-29.
19. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer:Asystematic reviewandmeta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189-199; discussion 199-201.
20. Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/ gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010;28(suppl 18s):LBA4518a.
21. Cognetti F, Ruggeri EM, Felici A et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: An Italian, multicenter, randomized phase III trial. Ann Oncol 2012;23:695-700.
22. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
23. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group);European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Groupet al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol 2011;29: 2171-2177.
24. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International Collaboration of Trialists. Lancet 1999;354:533-540.
25. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:202-205;discussion 205-206.
26. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
27. Dash A, Pettus JA IV, Herr HW et al. A role for neoadjuvant gemcitabine plus cisplatin in muscleinvasive urothelial carcinoma of the bladder: A retrospective experience. Cancer 2008;113:2471-2477.
28. Fairey AS, Daneshmand S, Quinn D et al. Neoadjuvantchemotherapywith gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol Oncol 2012. [Epub ahead of print].
29. Weight CJ, Garcia JA, Hansel DE et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series. Cancer 2009; 115:792-799.
30. David KA, Milowsky MI, Ritchey J et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. J Urol 2007;178:451-454.
31. Miles BJ, Fairey AS, Eliasziw M et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010;4:263-267.
32. Feifer AH, Taylor JM, Tarin TV et al. Maximizing cure for muscle-invasive bladder cancer: Integration of surgery and chemotherapy. Eur Urol 2011; 59:978-984.
33. Donat SM. Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: Strategy versus reality. J Natl Compr Canc Netw 2009;7:40-47.
34. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: Evidence from the National Cancer Database, 2003 to 2007. J Urol 2011;185:72-78.
35. Schrag D, Mitra N, Xu F et al. Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the Medicare population. Urology 2005;65:1118-1125.
36. Raj GV, Karavadia S, Schlomer B et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011;117:276-282.
37. Galsky MD, Hahn NM, Rosenberg J et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011;29:2432-2438.
38. Agrawal Y, Platz EA, Niparko JK. Prevalence of hearing loss and differences by demographic characteristicsamong US adults: Data from the National Health and Nutrition Examination Survey, 1999-2004. Arch Intern Med 2008;168:1522-1530.
39. Inzitari M, Carlo A, Baldereschi M et al. Riskand predictors of motor-performance decline in a normally functioning population-based sample of elderly subjects: The Italian Longitudinal Study on Aging. J Am Geriatr Soc 2006;54:318-324.
40. Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107:506-513.
41. Canter D, Viterbo R, Kutikov A et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011;77:160-165.
42. Hussain SA, Palmer DH, Lloyd B et al. Astudy of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett 2012;3:855-859.
43. Blaveri E, Brewer JL, Roydasgupta R et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005;11:7012-7022.
44. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009;4:127-150.
45. Aveyard JS, Skilleter A, Habuchi T et al. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80:904-908.
46. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-680.
47. Askham JM, Platt F, Chambers PA et al. AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010;29:150-155.
48. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011;58:1054-1063.
49. Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
50. Chappell WH, Steelman LS, Long JM et al. Ras/ Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways inhumanhealth. Oncotarget 2011;2:135-164.
51. Fujita J, Yoshida O, Yuasa Y et al. Ha-ras oncogenesare activatedbysomatic alterations inhuman urinary tract tumours. Nature 1984;309:464-466.
52. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-5273.
53. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
54. Wong YN, Litwin S, Vaughn D et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012;30:3545-3551.
55. Pruthi RS, Nielsen M, Heathcote S et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results. BJU Int 2010;106:349-354.
56. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218-2224.
57. Galsky MD, Hahn NM, Powles T et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013;11:175-181.
58. Ivy SP, Siu LL, Garrett-Mayer E et al. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: A report from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 2010;16: 1726-1736.
59. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27(suppl 15s):9000a.
60. Lee JK, Havaleshko DM, Cho H et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104:13086-13091.
61. Smith SC, Baras AS, Lee JK et al. The COXEN principle: Translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 2010;70: 1753-1758.
62. Dreicer R. The future of drug development in urothelial cancer. J Clin Oncol 2012;30:473-475.